GNLX vs IOVA
GNLX: Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and trigger personalized anti-tumor immune responses. IOVA: Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma through centralized manufacturing and clinical innovation.
Side-by-side fundamentals
| Metric | GNLX | IOVA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.96 | $5.17 | |
| Market cap as of 2026-07-23 | $131M | $2.3B | |
| Net margin as of 2026-07-23 | -115587.5% | -123.9% | IOVA higher |
| Gross margin as of 2026-07-23 | n/a | +36.7% | |
| Operating margin as of 2026-07-23 | -117650.0% | -127.2% | IOVA higher |
| ROE as of 2026-07-23 | -174.6% | -50.2% | IOVA higher |
| ROA as of 2026-07-23 | -123.6% | -38.8% | IOVA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | GNLX lower |
| Revenue growth (YoY) as of 2026-07-23 | -91.0% | +34.3% | IOVA higher |
| Revenue CAGR (3y) SEC XBRL | -91.0% | +1388.7% | IOVA higher |
| Beta as of 2026-07-23 | 0.57 | 0.68 | |
| 1-year return as of 2026-07-22 close | -17.7% | +120.1% | IOVA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.